The PD-1 And PD-L1 Inhibitors Market is being driven by Increasing prevalence of cancer
The PD-1 And PD-L1 Inhibitors Market is expected to grow at a CAGR of 18.3% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 49295.2 million. The PD-1 and PD-L1 inhibitors market is characterized by a significant presence of major pharmaceutical companies, each bringing innovative therapies to the table for the treatment of various types of cancer. The proven efficacy of approved PD-1 and PD-L1 inhibitors, such as OPDIVO, KEYTRUDA, and IMFINZI, has fueled an increasing demand for these inhibitors. Companies are investing heavily in research and development of advanced therapies to address various cancer indications, with several promising treatments in late-stage clinical trials. Approved PD-1 and PD-L1 inhibitors are also being explored in clinical trials for multiple cancer indications due to their effectiveness in disrupting the PD-1 and PD-L1 signaling pathways, which contribute to cancer cell growth.
Get more information on PD-1 And PD-L1 Inhibitors Market by requesting a sample report
Which Factors Are Causing a Surge in Market Growth?
The market is segmented based on Application (Solid tumors, Blood-related tumors) Geography (North America, Europe, Asia, Rest of World (ROW)).
According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows:
Rich Experience: 20+ years leading global market research, trusted insights across industries.
Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.
Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.
Key Features in PD-1 And PD-L1 Inhibitors Market Research Report
Find out which segment is leading the market by accessing the free PDF report
PD-1 and PD-L1 inhibitors are a class of immune checkpoint inhibitors that target the interaction between checkpoint proteins PD-1 and PD-L1 on normal and cancer cells, allowing T cells to resume their immune attack on foreign cells, including germs and cancer cells. These monoclonal antibodies, such as Pembrolizumab, Nivolumab, Cemiplimab, Atezolizumab, Avelumab, Durvalumab, Ipilimumab, Tremelimumab, and Relatlimab, function as an "off switch" for the immune response against melanoma and other cancers. However, they may cause side effects like diarrhea, fatigue, cough, nausea, skin rash, and poor appetite due to overactive immune response.
The global life sciences tools and services market encompasses organizations involved in the research and development (R&D) of various product categories, including capital equipment, instruments, accessories, and consumables for pharmaceuticals and biotechnology, as well as laboratory diagnosis of various diseases. Key drivers fueling market growth include the increasing global population aging, with the proportion of those over 60 years predicted to rise significantly. This demographic shift will necessitate advancements in healthcare and life sciences, particularly in the realm of immune response modulation through checkpoint proteins, such as PD-1 and PD-L1. Immune checkpoint inhibitors, including monoclonal antibodies, are crucial in enhancing T cell immune response against normal, foreign, germ, and cancer cells. The market size is calculated based on the combined revenue generated by manufacturers of equipment, supplies, pharmaceuticals, biotechnology, and life science tools and services.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
